A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) Meeting Abstract
| Authors: | Younes, A.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Hong, X.; Zhu, J.; Samoilova, O.; Suh, C.; Matsumura, I.; Lopez-Hernandez, A.; Duhrsen, U.; Thieblemont, C.; Carey, J.; Liu, G.; Shreeve, S. M.; Sun, S.; Vermeulen, J.; Staudt, L. M.; Wilson, W. H. |
| Abstract Title: | A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837602162 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-112988 |
| Notes: | Meeting Abstract: 784 -- Source: Wos |
